<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-559
Date of Submission: 2024-10-05

This report was submitted by a Patient from Peterson, Mooney and Cervantes Medical Center concerning patient ANON-PX-2809. The subject is a 63-year-old male with a significant medical history including chronic kidney disease, hypertension, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intramuscular route at a dosage of 187mg, initiated on 2024-07-21 for Hypercholesterolemia and discontinued on 2024-09-26; Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 76mg, initiated on 2024-07-21 for Thromboembolism prevention and discontinued on 2024-09-26.

On approximately 2024-08-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Anaphylaxis. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Total social listen east. Network speech toward also fight unit.</data>
report_id: ADR-2024-559
report_date: '2024-10-05'
patient_details:
  patient_id: ANON-PX-2809
  gender: Male
  relevant_history:
  - chronic kidney disease
  - hypertension
  - coronary artery disease
  age_at_reaction: 63
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 187mg
  route_of_administration: Intramuscular
  start_date: '2024-07-21'
  indication_for_use: Hypercholesterolemia
  end_date: '2024-09-26'
- drug_name: Warfarin
  dosage: 76mg
  route_of_administration: Intravenous
  start_date: '2024-07-21'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
  end_date: '2024-09-26'
adverse_reactions:
- symptom_name: Hepatotoxicity
  onset_date: '2024-08-01'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2024-08-01'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 1
reporting_facility: Peterson, Mooney and Cervantes Medical Center
reporter_type: Patient
notes: Total social listen east. Network speech toward also fight unit.
